Fireside chat with Antoine Yver

Over several decades, Antoine Yver has worked on some of the most important cancer drugs currently available, most notably the big three at AstraZeneca: Tagrisso, Lynparza and Enhertu. His development work on Tagrisso stands out for its ultra-fast 2 year, 7 month long development period — from first dose to first approval. He and Editor John Carroll will talk about where the big cancer drugs of the future are coming from. And how long that takes.

Did we dodge the worst of a downturn? Where the market stands on deals and IPOs

This year has seen a strong start to M&A, with large takeovers finally happening in cancer and immunology and big drugmakers work to spend their Covid cash and reload pipelines.

Macroeconomic conditions appear to be improving, as well, which could open the window for IPOs. Our panel of experts will lead a discussion on how the appetite for deals and new offerings stacks up against questions about antitrust, lingering worries about a recession, and a set of potential targets that is still in shakeout mode.

How to be one of the best biotech CEOs in the business

What are the essential ingredients for a European biotech CEO in this uncertain environment? How do you establish an international reputation? How do you develop the right partnerships and confront the biggest challenges? How do you recruit an outstanding executive crew? And just how do you deal with the media in this field? I’ll be moderating a provocative roundtable discussion on what it takes today to be the best in the field — and how rare that is.

Fireside chat with John Tsai

John Tsai’s recent emergence as CEO of the biotech startup Forcefield completes a journey that took him from the head of two of the largest drug development organizations in the world — Novartis and Amgen — to the helm of a tightly focused biotech with a very big goal in mind. We’ll discuss the nature of R&D in a turbulent time, and what biotechs need to do to compete and thrive in large arenas like cardio.

European biotech VCs recalibrate and refocus

It’s no surprise that the post-Covid era has seen a system-wide reevaluation of the role VCs play in startups. We’ll gather a top group of the continent’s most active VCs to look at the brave new world they face, and get their views on which biotechs will get funding in 2024. Features panelists from Novo, Sofinnova, Medicxi and more.

Turning on the Spigot: New Funding for Private Investments from the UK

Changes to how UK pensions can invest their money could open up billions of dollars in new funding for biotechs, in particular for UK and European companies. Our panelist will talk about the fundraising environment in the UK and Europe, both for companies and funds, and how it's evolving in the years to come.

Annex 1: A guide to EMA's new sterile product manufacturing requirements

Starting August 25, 2023, all pharmaceutical companies that produce sterile products are subject to comply with revisions to the EU GMP Annex 1: “Manufacture of Sterile Medicinal Products." With an increased emphasis on risk management and contamination control strategies, these new EMA requirements have prompted questions across the industry about manufacturing and technology preparedness.This expert panel will explore:

• Why the EMA required this update and its effect on the industry as a whole
• The impact of Annex 1 on sterile fill/finish manufacturing — and what to keep in mind with equipment selection, product approvals and technologies such as RABS versus isolators
• How companies can meet these terms — and understand what's offered as guidance versus requirement

Fireside chat with Shreeram Aradhye

Shreeram Aradhye is in charge of one of the largest pipelines in development in biopharma, and he’s had his hands full tailoring a strategy aimed at raising Novartis’s position in the all-important US market as well as looking for the next big blockbusters to in-license or buy. Endpoints Editor John Carroll and Shreeram will go one-on-one in this focused discussion on strategy, R&D philosophy and what it takes to succeed in Big Pharma drug research today.